BMRN
Price
$57.54
Change
-$0.46 (-0.79%)
Updated
Aug 15 closing price
Capitalization
11.05B
65 days until earnings call
IDYA
Price
$24.33
Change
-$0.04 (-0.16%)
Updated
Aug 15 closing price
Capitalization
2.13B
85 days until earnings call
Interact to see
Advertisement

BMRN vs IDYA

Header iconBMRN vs IDYA Comparison
Open Charts BMRN vs IDYABanner chart's image
BioMarin Pharmaceutical
Price$57.54
Change-$0.46 (-0.79%)
Volume$2.53M
Capitalization11.05B
IDEAYA Biosciences
Price$24.33
Change-$0.04 (-0.16%)
Volume$1.01M
Capitalization2.13B
BMRN vs IDYA Comparison Chart in %
Loading...
BMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMRN vs. IDYA commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a Hold and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (BMRN: $57.54 vs. IDYA: $24.33)
Brand notoriety: BMRN and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMRN: 120% vs. IDYA: 99%
Market capitalization -- BMRN: $11.05B vs. IDYA: $2.13B
BMRN [@Biotechnology] is valued at $11.05B. IDYA’s [@Biotechnology] market capitalization is $2.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMRN’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • BMRN’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than BMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMRN’s TA Score shows that 5 TA indicator(s) are bullish while IDYA’s TA Score has 5 bullish TA indicator(s).

  • BMRN’s TA Score: 5 bullish, 4 bearish.
  • IDYA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than BMRN.

Price Growth

BMRN (@Biotechnology) experienced а -3.23% price change this week, while IDYA (@Biotechnology) price change was +5.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

BMRN is expected to report earnings on Oct 22, 2025.

IDYA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BMRN($11B) has a higher market cap than IDYA($2.13B). IDYA YTD gains are higher at: -5.331 vs. BMRN (-12.460). BMRN has higher annual earnings (EBITDA): 777M vs. IDYA (-356.46M). BMRN has more cash in the bank: 1.27B vs. IDYA (693M). IDYA has less debt than BMRN: IDYA (26M) vs BMRN (602M). BMRN has higher revenues than IDYA: BMRN (2.95B) vs IDYA (7M).
BMRNIDYABMRN / IDYA
Capitalization11B2.13B516%
EBITDA777M-356.46M-218%
Gain YTD-12.460-5.331234%
P/E Ratio16.97N/A-
Revenue2.95B7M42,143%
Total Cash1.27B693M184%
Total Debt602M26M2,315%
FUNDAMENTALS RATINGS
BMRN vs IDYA: Fundamental Ratings
BMRN
IDYA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
62
Fair valued
PROFIT vs RISK RATING
1..100
10072
SMR RATING
1..100
7196
PRICE GROWTH RATING
1..100
7746
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMRN's Valuation (56) in the Biotechnology industry is in the same range as IDYA (62) in the null industry. This means that BMRN’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (72) in the null industry is in the same range as BMRN (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to BMRN’s over the last 12 months.

BMRN's SMR Rating (71) in the Biotechnology industry is in the same range as IDYA (96) in the null industry. This means that BMRN’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Price Growth Rating (46) in the null industry is in the same range as BMRN (77) in the Biotechnology industry. This means that IDYA’s stock grew similarly to BMRN’s over the last 12 months.

BMRN's P/E Growth Rating (99) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that BMRN’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMRNIDYA
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
64%
Bullish Trend 4 days ago
83%
Momentum
ODDS (%)
Bearish Trend 4 days ago
72%
Bullish Trend 4 days ago
75%
MACD
ODDS (%)
Bearish Trend 4 days ago
72%
Bearish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
64%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
61%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 6 days ago
60%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
62%
Bearish Trend 4 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
68%
Bearish Trend 4 days ago
77%
Aroon
ODDS (%)
Bullish Trend 4 days ago
47%
Bullish Trend 4 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
BMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EZJ49.251.61
+3.39%
ProShares Ultra MSCI Japan
ECAT16.69N/A
N/A
BlackRock ESG Capital Allocation Term Trust
TCPB50.85-0.12
-0.23%
Thrivent Core Plus Bond ETF
NPCT10.96-0.07
-0.63%
Nuveen Core Plus Impact Fund
SLX69.57-0.48
-0.69%
VanEck Steel ETF

BMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMRN has been loosely correlated with ITOS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BMRN jumps, then ITOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMRN
1D Price
Change %
BMRN100%
-0.79%
ITOS - BMRN
50%
Loosely correlated
N/A
IBO - BMRN
42%
Loosely correlated
+1.66%
IONS - BMRN
42%
Loosely correlated
+2.17%
DNTH - BMRN
40%
Loosely correlated
+2.42%
IDYA - BMRN
40%
Loosely correlated
-0.16%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with SYRE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-0.16%
SYRE - IDYA
61%
Loosely correlated
+0.53%
NRIX - IDYA
61%
Loosely correlated
+0.19%
IMNM - IDYA
61%
Loosely correlated
+3.42%
CGON - IDYA
60%
Loosely correlated
-1.00%
XENE - IDYA
58%
Loosely correlated
+0.71%
More